scholarly journals Reducing blood loss during open myomectomy with intravenous versus topical tranexamic acid: A double-blinded randomized placebo-controlled trial

2018 ◽  
Vol 23 (3) ◽  
pp. 225-231 ◽  
Author(s):  
Nahla W. Shady ◽  
Hany F. Sallam ◽  
Huda Fahmy
Keyword(s):  
Blood Loss ◽  
Tranexamic Acid ◽  
Controlled Trial ◽  
Double Blinded ◽  
Topical Tranexamic Acid

scholarly journals Adjunctive IV tranexamic acid versus topical tranexamic acid application of the placental bed for prevention of postpartum hemorrhage in women with placenta previa: a randomized controlled trial

2017 ◽  
Vol 6 (12) ◽  
pp. 5205
Author(s):  
Nahla W. Shady ◽  
Hany F. Sallam
Keyword(s):  
Randomized Controlled Trial ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Caesarean Delivery ◽  
Placenta Previa ◽  
Controlled Trial ◽  
Acid Group ◽  
Randomized Controlled ◽  
Group I ◽  
Topical Tranexamic Acid

Background: Placenta previa one of the famous etiology of excessive blood loss during and after cesarean section. The objective of this study was to determine the effect of prophylactic adjunctive IV versus topical tranexamic acid (TA) on calculated and measured blood loss during and after caesarean section due to placenta previa compared with standard IV oxytocin alone.Methods: In this double-blind randomized controlled trial, 120 women were undergoing caesarean delivery for placenta previa (PP) were randomly allocated to receive 10 IU oxytocin IV after placental delivery, or receive 1 gm tranexamic acid IV just before skin incision plus 10 IU oxytocin IV after placental delivery or received 10 IU oxytocin IV after placental delivery plus 2 gm topical tranexamic acid applied on placental bed. The main outcome was to measure blood loss during and 4-hour post caesarean delivery.Results: 120 women were enrolled (n = 40 in each group). Both groups of women received IV tranexamic acid (Group II) and topical tranexamic acid (Group III) showed great reduction in intraoperative and 4 hours post-operative blood loss compared with (Group I) which received 10 IU oxytocin only (P = 0.0001, 0.0001, 0.0001, 0.0001), so the overall estimated blood loss in group II and III showed highly reduction compared with group I (P = 0.0001, 0.0001).Conclusions: Prophylactic adjunctive TA topical application on the placental bed or iv administration reduces blood loss during and after caesarean delivery in women with a placenta previa. novel application of topical tranexamic acid on the placental bed is effective in reduce intraoperative and postoperative bleeding in comparison with IV route with elimination of theoretical risk of thrombi embolism complication with IV rout.

scholarly journals The Combined Effect of Intravenous and Topical Tranexamic Acid in Liposuction: A Randomized Double-Blinded Controlled Trial

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Nicolas M Abboud ◽  
Ayush K Kapila ◽  
Sofie Abboud ◽  
Elie Yaacoub ◽  
Marwan H Abboud
Keyword(s):  
Tranexamic Acid ◽  
Controlled Trial ◽  
Combined Effect ◽  
Control Group ◽  
Postoperative Evaluation ◽  
Level Of Evidence ◽  
Combined Use ◽  
Double Blinded ◽  
Topical Tranexamic Acid ◽  
Local Use

Abstract Background Tranexamic acid (TXA) use in surgical procedures due to its hemostatic effects has been gaining an increased interest. In plastic surgery, the effects of TXA have been studied intravenously (IV), and there have been some reports regarding local use. Objectives A comparative study examining the combined effect of IV and local TXA was conducted. Methods A randomized double-blinded controlled trial was performed for patients undergoing breast reduction treatment with liposuction and resection following the power-assisted liposuction mammaplasty (PALM) technique. All patients received 5 mL IV of 0.5 g/5 mL TXA on induction. Before installation, one researcher prepared two solutions of 1 L normal saline: one with 5 mL of 0.5 g/5 mL TXA associated with epinephrine 1:100,000 and the other with only epinephrine 1:100,000. These were randomly infiltrated in either the left or right breast. Clinical dermal bleeding was assessed for both breasts after deepithelialization. The lipoaspirate from these breasts was then compared with each other. A postoperative evaluation at 24 hours was performed to compare the ecchymosis rate. Results Ratios of decanted volume to total lipoaspirate was measured in bottles and compared between breasts. There was a statistical difference (P = 0.0002) in the ratio of decanted to lipoaspirated volume when comparing the control group (ratio: 0.21) with the treatment group (0.13). Video analysis revealed decreased dermal bleeding in the TXA group and postoperative evaluation less ecchymosis. Conclusions The combined use of IV and local TXA can help reducing blood loss in liposuction as measured by decantation in separate drain bottles and as assessed clinically preoperatively and postoperatively. Level of Evidence: 2

Pre-operative tranexemic acid vs. etamsylate in reducing blood loss during elective cesarean section: randomized controlled trial

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Haitham Torky ◽  
El-Sayed El-Desouky ◽  
Ibrahim Abo-Elmagd ◽  
Attia Mohamed ◽  
Ahmad Abdalhamid ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Side Effects ◽  
Blood Loss ◽  
Cesarean Section ◽  
Tranexamic Acid ◽  
Controlled Trial ◽  
Elective Cesarean Section ◽  
Randomized Controlled ◽  
Elective Cesarean ◽  
Double Blinded

AbstractObjectivesTo investigate whether etamsylate may be an alternative to tranexamic acid in reduction of blood loss during elective cesarean section.MethodsProspective double-blinded multi-center randomized controlled trial involving 180 qualified women equally divided into three groups each containing 60 women received either tranexamic acid, etamsylate or placebo 20 min before elective cesarean section and blood loss was estimated.ResultsMean blood loss, cases needing blood transfusion and cases needing further interventions were significantly lower in tranexamic acid and etamsylate group than placebo group, while mean postoperative hemoglobin and hematocrite were significantly higher in both tranexamic acid and etamsylate as compared to placebo.ConclusionsEtamsylate is an effective second-line therapy (after tranexamic acid) in reducing blood loss during elective cesarean section with low risk of side effects, therefore, it can be an effective alternative to tranexamic acid in cases with contraindications or anticipated to be at high-risk of developing side effects from tranexamic acid.

OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial

2018 ◽  
Vol 29 (3) ◽  
pp. 239-244 ◽  
Author(s):  
Andrew Fraval ◽  
Sam Duncan ◽  
Theresa Murray ◽  
Jeremy Duggan ◽  
Oren Tirosh ◽  
...  
Keyword(s):  
Length Of Stay ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Hip Arthroplasty ◽  
Anterior Approach ◽  
Primary Outcome ◽  
Controlled Trial ◽  
Control Group ◽  
Thigh Swelling ◽  
Double Blinded

Background: We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period. We also compare the effect of aspirin and enoxaparin as DVT chemoprophylactic agents. Methods: We conducted a single-centre randomised, double-blinded, placebo-controlled trial. 105 patients were randomised to receive either tranexamic acid or an equivalent volume of normal saline with enoxaparin used as DVT chemoprophylaxis. The primary outcome measure was thigh swelling. Blood loss and the incidence of blood transfusions was also recorded. Secondary outcome measures including postoperative functional scores and mobility, pain scores and length of stay. We also compared and pooled the results of a previous study with the same study intervention methodology which used aspirin as DVT chemoprophylaxis instead of enoxaparin. Results: There were no statistically significant differences between the primary outcome of thigh swelling. There was significantly less intraoperative blood loss observed in the tranexamic acid (TXA) group (0.510 L, SD 0.210) compared with the control group (0.698, SD 0.301) ( p < 0.001). The estimated blood loss was also significantly less in the TXA group (1.130 L, SD 0.311) compared with the control group (1.48 L, SD 0.510) ( p < 0.001). Pooled data of both consecutive trials showed there was a statistically significant reduction in length of stay for those that received TXA (3.72 days, SD 0.83 versus 4.24 days, SD 0.97, p < 0.001). There was also a statistically significant increased risk of a transfusion in the control group as compared those that received TXA (OR 5.5, 1.188 to 25.449, p = 0.029). There was no difference in blood loss between DVT chemoprophylactic agents. Interpretation: TXA is an effective agent in reducing blood loss in THR using the anterior approach and was not affected by choice of DVT chemoprophylaxis. Patients who received TXA had fewer transfusions and a reduction in their length of stay. The blood conserving effect of TXA was not associated with improved postoperative recovery across the measures of pain and mobility. Clinical trials registration: ANZCTR number: ACTRN12616000606482.

Sign in / Sign up

Export Citation Format

Share Document